Because FHV - 1 can induce tissue injury directly as a result of viral cytolysis or indirectly
through immunopathologic processes mediated by inflammatory cells, treatment of FHV - 1 keratoconjunctivitis involves: 1) prevention of viral replication; 2)
immunomodulation; and, 3) prevention of secondary bacterial infection.